RxDoctor Payments Data

Marco Antonio Frias, MD

Family Medicine · Binghamton, NYNPI 1356993281

Payments from drug & device makers

$5,771in general payments, 2019–2025

Across 323 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$919
  • Novo Nordisk$584
  • GSK$527
  • Pfizer$454
  • Lilly USA, LLC$336
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,771 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$48,535
Medicare patients
176
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$180,449
JardianceEmpagliflozin124$161,230
OzempicSemaglutide83$119,770
RybelsusSemaglutide48$100,994
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$68,519
FarxigaDapagliflozin Propanediol41$58,777
EntrestoSacubitril/Valsartan23$31,223
JanuviaSitagliptin Phosphate27$29,545
TrulicityDulaglutide16$26,390
XareltoRivaroxaban14$20,277
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$19,733
MyrbetriqMirabegron19$17,401
LinzessLinaclotide13$13,575
Breo ElliptaFluticasone/Vilanterol24$10,375
Combivent RespimatIpratropium/Albuterol Sulfate14$10,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$584$220,765131 claims
PfizerEliquis$454$180,449135 claims
Boehringer IngelheimJardiance, Combivent Respimat$189$171,322138 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$919$82,36970 claims
GSKTrelegy Ellipta, Breo Ellipta$527$78,89387 claims
MerckJanuvia, Belsomra$97$34,15839 claims
NovartisEntresto$115$31,22323 claims
Lilly USA, LLCTrulicity$336$26,39016 claims
AbbVieLinzess, Synthroid$1,361$16,23663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.

Other family medicine in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →